Prostate cancer progresses in stages, and understanding where your cancer falls in this spectrum matters when looking at treatment paths. Advanced prostate cancer typically refers to cancer that has spread beyond the prostate gland itself—either to nearby lymph nodes, bones, or other organs. This is different from early-stage prostate cancer, which remains confined to the prostate.
Learn About Paying Your FGUA Bill Online →
The stage of cancer affects which treatments doctors consider most useful. When cancer spreads to distant parts of the body, it's called metastatic prostate cancer. According to the American Cancer Society, about 5% of men are diagnosed with metastatic prostate cancer at the time of their initial diagnosis. For others, advanced cancer develops years or even decades after initial treatment of early-stage disease.
One critical distinction in advanced prostate cancer is whether it responds to hormone therapy. Most prostate cancers depend on the hormone testosterone to grow. Doctors may use the term "hormone-sensitive" or "hormone-resistant" (also called castration-resistant) to describe this trait. A cancer that was initially responsive to hormone therapy but later stopped responding falls into the castration-resistant category. This classification significantly influences which medicines your medical team might recommend.
Doctors also look at PSA levels (prostate-specific antigen is a protein produced by the prostate), the Gleason score (which describes how abnormal cancer cells look under a microscope), and imaging results to understand how aggressive the cancer is and where it has spread. These factors together create a fuller picture than any single measure alone.
Practical takeaway: Before exploring treatment options, gather your pathology report and ask your doctor specifically what stage your cancer is, whether it's hormone-sensitive or hormone-resistant, and what your PSA level and Gleason score are. These details will make conversations about different treatments more meaningful.
Hormone therapy, also called androgen deprivation therapy (ADT), works by lowering testosterone levels or blocking testosterone's effects on cancer cells. Since most prostate cancer cells need testosterone to grow, reducing this hormone can slow or temporarily stop cancer progression. This approach has been a cornerstone of advanced prostate cancer treatment for decades.
Free Guide to Pay by Plate Illinois Billing →
There are several ways doctors deliver hormone therapy. Luteinizing hormone-releasing hormone (LHRH) agonists are injections or implants that signal the body to produce less testosterone. Common medications in this category include leuprolide (Lupron), goserelin (Zoladex), and triptorelin (Trelstar). These are typically given as injections every 1, 3, 4, or 6 months, depending on the specific formulation. Another class, LHRH antagonists like degarelix (Firmagon), works faster and may be chosen when quick testosterone reduction matters.
A third approach uses antiandrogens—medications that block testosterone from attaching to cancer cells even when testosterone levels remain present. Traditional antiandrogens include bicalutamide (Casodex) and flutamide (Eulexin). Newer antiandrogens called next-generation antiandrogens (like enzalutamide, abiraterone, and apalutamide) are often more powerful and may be combined with other treatments for advanced cases.
Doctors sometimes use combination hormone therapy, pairing an LHRH agonist with an antiandrogen from the start of treatment. Research published in journals like the New England Journal of Medicine has shown that this combined approach can delay cancer progression longer than hormone therapy alone in certain situations. However, hormone therapy eventually stops working for many men—this is when doctors discuss castration-resistant options.
Side effects of hormone therapy include hot flashes, loss of sexual function, fatigue, mood changes, bone density loss, and weight gain. These effects may improve or persist depending on individual factors and the duration of treatment. Some men take short breaks from hormone therapy to reduce long-term side effects, a strategy called intermittent androgen deprivation.
Practical takeaway: If your doctor recommends hormone therapy, ask about the specific drug they're suggesting, the frequency of dosing, expected side effects for that particular medication, and whether it will be combined with other treatments. Understanding these details upfront helps you prepare physically and emotionally.
When hormone therapy stops working, chemotherapy and immunotherapy become important options. Chemotherapy uses chemicals to kill rapidly dividing cells, including cancer cells. For advanced prostate cancer, docetaxel (Taxotere) and cabazitaxel (Jevtana) are the most commonly used chemotherapy drugs. Docetaxel is often combined with hormone therapy even before cancer becomes castration-resistant, particularly in men with high disease burden (meaning extensive spread).
Free Guide to Mold Removal Methods for Walls →
Chemotherapy for prostate cancer is typically given intravenously every 3 weeks in cycles lasting several months. A man might receive 6 to 10 cycles depending on how well his cancer responds and how he tolerates the side effects. Unlike some cancer chemotherapies, prostate cancer regimens often allow men to remain relatively functional during treatment—many continue working or managing daily activities with modifications.
Immunotherapy represents a newer category that harnesses the body's own immune system to fight cancer. Sipuleucel-T (Provenge) is a vaccine-like treatment specifically designed for castration-resistant prostate cancer. Rather than being injected like a standard vaccine, this treatment is created by collecting immune cells from a patient's blood, training them to recognize prostate cancer cells in a laboratory, and then returning them to the patient's body to attack cancer.
Checkpoint inhibitors represent another immunotherapy approach. These drugs remove "brakes" that cancer cells place on the immune system. Pembrolizumab (Keytruda) and nivolumab (Opdivo) have shown promise in prostate cancer cases with specific genetic characteristics, though they're not yet standard for all men with advanced disease. Researchers continue studying how immunotherapy might work better when combined with other treatments.
Both chemotherapy and immunotherapy carry different side effect profiles than hormone therapy. Chemotherapy side effects can include bone marrow suppression (affecting blood cell production), mouth sores, diarrhea, and nerve damage in hands and feet. Immunotherapy side effects stem from an overly activated immune system and may include fatigue, rash, joint pain, or inflammation of organs. These effects vary significantly between individuals.
Practical takeaway: Request a conversation about how your doctor measures whether chemotherapy or immunotherapy is working—typically through PSA levels, imaging scans, or both. Knowing the plan for monitoring progress helps you understand whether to continue, change, or stop treatment.
One of the most significant advances in advanced prostate cancer treatment comes from understanding that some men carry genetic mutations affecting DNA repair mechanisms. These mutations, particularly in genes like BRCA1, BRCA2, and others in the homologous recombination repair pathway, make cancer cells vulnerable to specific targeted drugs.
How to Delete Your Fitbit Account Guide →
PARP inhibitors (poly ADP-ribose polymerase inhibitors) target cancers with these DNA repair defects. Olaparib (Lynparza) and rucaparib (Rubraca) have been studied in men with castration-resistant prostate cancer who carry these mutations. These drugs essentially prevent cancer cells from fixing DNA damage, causing them to die. For men whose tumors carry these specific mutations, PARP inhibitors may extend the time before cancer progresses compared to standard chemotherapy.
Similarly, folic acid metabolism inhibitors like methotrexate derivatives have been studied for prostate cancer with specific genetic changes. These represent another example of precision medicine—matching treatment to the individual characteristics of a person's cancer rather than using a one-size-fits-all approach.
To determine whether you might benefit from these targeted treatments, your doctor will order genetic testing of your cancer tissue or sometimes blood tests. This testing looks for specific mutations that predict response to targeted drugs. Not all men with advanced prostate cancer will have these mutations, so testing is an important first step. The testing itself is relatively straightforward from a patient perspective—usually just involving a tissue sample already collected during biopsy or a blood draw.
The benefit of targeted approaches lies in their potential to work better in specific populations while sometimes offering
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.